Etranacogene Dezaparvovec. Infusion Suppliers & Bulk Manufacturers

Available Forms: Intravenous infusion

Available Strengths: Single infusion product designed to produce sustained factor IX levels in hemophilia B patients, dosage individualized based on patient weight

Reference Brands: Hemgenix (US & EU)

Category: Cell & Gene Therapies

Etranacogene dezaparvovec (AMCECVIT) is a gene therapy that delivers a functional FIX gene to treat hemophilia B. It provides sustained, long-term factor IX production, reducing bleeding episodes, decreasing need for regular infusions, and improving quality of life with a one-time administration in suitable patients. Etranacogene dezaparvovec. infusion is available in Intravenous infusion and strengths such as Single infusion product designed to produce sustained factor IX levels in hemophilia B patients, dosage individualized based on patient weight. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Etranacogene dezaparvovec. infusion is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Etranacogene dezaparvovec. infusion can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Etranacogene dezaparvovec (AMECVIT) is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP and MDR standards. In the US, FDA approval involved extensive clinical validation, safety assessments, and comparability data. In the EU, CE marking certifies conformity with MDR regulations. These gene therapies undergo validation, stability testing, and audits, supported by comprehensive documentation including safety profiles, clinical trial results, and manufacturing practices. For licensing procedures, approved dossiers, and regulatory updates, visit Pharmatradz. Ensuring regulatory compliance guarantees access to innovative gene therapies supporting hemophilia B management worldwide, promoting effective treatment and improved patient outcomes.